Does Taurine Really Slow Aging? What a 2025 NIH Study Just Revealed
Key Takeaways
- A 2023 Science paper showed taurine declines with age in animals and supplementation extended lifespan, triggering a major supplement trend
- A 2025 NIH study using 50+ years of Baltimore Longitudinal Study human data found taurine levels often do NOT decline with age in people — and are inconsistently associated with aging outcomes
- The “taurine deficiency drives aging” hypothesis is not disproven, but it is substantially weakened in humans
- Taurine still has legitimate research support for cardiovascular function, exercise performance, and antioxidant effects — just not necessarily for longevity extension
- The episode is a useful case study in how to evaluate longevity supplement claims before acting on animal data
Why Everyone Started Talking About Taurine in 2023
In June 2023, a paper published in Science sent taurine supplement sales soaring. The study, led by Vijay Yadav at Columbia University, found that taurine — an amino acid naturally present in meat, seafood, and to a lesser extent in the human body — declined with age in mice, rhesus monkeys, and humans. When the researchers supplemented middle-aged mice and monkeys with taurine, the animals lived significantly longer. Mice showed a 10–12% lifespan extension. The monkeys showed improvements in bone density, muscle strength, glucose regulation, and immune function.
The coverage was enormous. The paper was published in Science, which gave it scientific credibility. The finding that taurine is cheap, naturally occurring in food, and already found in energy drinks made it accessible and non-threatening. Within weeks, taurine supplements were flying off shelves.
The hypothesis was compelling: aging is partly driven by taurine deficiency. Replace what’s lost, extend healthspan.
What the 2025 NIH Study Found
In June 2025, researchers at the National Institutes of Health published a paper in Science that put that hypothesis to a serious test. Using data from the Baltimore Longitudinal Study of Aging — one of the longest-running human aging studies in existence, with participants tracked over multiple decades — they measured taurine levels across age groups and within the same individuals over time.
The results were strikingly different from what the 2023 animal data suggested. In the human longitudinal samples, taurine levels did not consistently decline with age. In many participants, taurine remained stable. In some, it actually increased. When the researchers looked at associations between taurine levels and health outcomes, they found those associations were inconsistent across age groups, cohorts, and species.
Critically, within-individual variation in taurine levels over time often exceeded the variation attributed to aging. In other words, factors like diet, activity level, stress, and individual biology created more noise than the aging signal the 2023 paper was pointing to.
The conclusion from the NIH team: taurine is unlikely to be a reliable biomarker for aging, and the deficiency narrative may not hold in humans the way it appeared to in animal models.
What This Does and Doesn’t Mean
The 2025 paper doesn’t prove taurine supplementation is useless. It challenges a specific claim: that aging in humans is driven by declining taurine levels that supplementation can reverse.
That distinction matters. There are two different questions at play here. First: does taurine decline with age in humans and does that decline drive aging? The 2025 data suggests no — or at least, not reliably and not universally. Second: does taurine supplementation produce health benefits regardless of whether deficiency was the original issue? That’s a separate question, and the answer is more nuanced.
Taurine has legitimate research support in several areas that don’t depend on the aging-deficiency hypothesis. Multiple randomized controlled trials have found that taurine supplementation improves cardiovascular markers — particularly blood pressure and arterial stiffness — in adults with elevated baseline risk. A 2023 meta-analysis in Nutrients found significant reductions in systolic blood pressure with taurine supplementation. Exercise performance research has consistently shown benefits for aerobic capacity and recovery.
These are real findings. They just aren’t longevity findings in the specific sense the 2023 paper implied.
The Animal-to-Human Translation Problem
The taurine episode is a particularly clear example of a recurring challenge in longevity science: animal models predict human outcomes poorly, especially for aging interventions.
Mice and humans age by different mechanisms, at vastly different rates, under vastly different dietary and environmental conditions. A supplement that reliably extends mouse lifespan by 10% may do nothing measurable in humans — or may work through entirely different pathways. The history of longevity interventions is littered with mouse results that didn’t translate: resveratrol, most antioxidants, and many caloric restriction mimetics have all shown more dramatic effects in rodents than in human trials.
This doesn’t make the animal data worthless — it’s still useful for identifying mechanisms and generating hypotheses. But “this extended mouse lifespan” is a starting point for human investigation, not a reason to start supplementing.
The 2023 taurine paper did include human correlation data — cross-sectional measurements showing that people with higher taurine had better health markers. The 2025 Baltimore data exposed the limitation of that approach: cross-sectional snapshots can look very different from longitudinal tracking of individuals over time. The former might capture dietary and lifestyle confounders that have nothing to do with aging specifically.
Who Should Still Consider Taurine
The evidence for taurine supplementation in longevity is now weaker than it appeared in 2023. That doesn’t mean there’s no case for taurine at all.
If you’re interested in cardiovascular protection — particularly blood pressure management — taurine has reasonable RCT support. Typical doses in cardiovascular research are 1–3 grams per day. Safety at these doses is well-established; taurine is one of the most abundant amino acids in the human body and is consumed in gram quantities through normal meat-containing diets.
If your primary motivation was longevity extension based on the 2023 animal data, the 2025 human evidence gives reason to recalibrate. You’re not in danger from taking taurine — the supplement is safe — but the specific hypothesis justifying it has been substantially weakened.
Athletes and physically active older adults may still find value in taurine for exercise performance and recovery, where the human trial data is more consistent.
How to Think About the Next Supplement Trend
The taurine story provides a useful framework for evaluating longevity supplement claims. There are three questions worth applying to any new finding:
First: is the primary data from animals or humans? If the exciting results are from mice or monkeys, file them under “promising mechanisms to watch” rather than “reasons to order this today.” Lifespan extension in rodents routinely fails to replicate in human trials. The 2025 taurine data is a reminder of how different that translation can be.
Second: is the human data cross-sectional or longitudinal? Cross-sectional studies (measuring a group at one point in time) can show associations that look causal but aren’t. The original taurine human data showed people with higher taurine levels had better health markers — but that correlation was complicated by lifestyle factors and didn’t hold up when the same people were tracked over time. Longitudinal data, especially when it tracks individuals over decades, is almost always more informative.
Third: who benefits if this claim is true? This doesn’t mean dismissing research from scientists with financial ties to the supplements they study. But it’s a variable worth noting. The taurine story was accelerated by media coverage that wasn’t primarily interested in methodological nuance.
What the Research Landscape Actually Supports
For adults interested in longevity-oriented supplementation, here’s where the evidence currently sits more solidly: autophagy-activating compounds like spermidine have longitudinal human data showing genuine age-related decline and population-level associations with cardiovascular and all-cause mortality. Senolytic flavonoids like fisetin and quercetin have emerging human trial data for physical function in aging. Berberine and metformin have strong human metabolic trial evidence. Omega-3 fatty acids have decades of RCT support for cardiovascular outcomes.
None of these have proven human lifespan extension either — that bar hasn’t been cleared by any supplement or drug in properly controlled human trials. But the evidence base for mechanism and population health outcomes is more robust than the pre-2025 case for taurine as a longevity intervention.
The Bottom Line
Taurine isn’t a dangerous supplement. If you’ve been taking it for cardiovascular support or exercise performance, there’s no compelling reason to stop based on the 2025 data. The specific longevity premise — replace declining taurine to slow aging — is the part that’s been weakened.
The more useful takeaway from this episode might be the lesson about supplement evaluation itself. Animal lifespan data is routinely exciting and routinely overstated. The supplements with the most durable human evidence base are usually less dramatic to read about than the ones that just extended mouse lifespan by 12%.
👉 Download our free guide: How to Evaluate Longevity Supplements — A Framework for Evidence-Based Decisions
FAQ
Should I stop taking taurine after the 2025 NIH study?
Not necessarily. If you’re taking taurine for cardiovascular or exercise performance reasons, those evidence bases are separate and still hold. If longevity extension was your primary motivation, the case is now weaker.
What exactly did the 2025 NIH study find?
NIH researchers used decades of Baltimore Longitudinal Study blood samples and found taurine levels in humans often don’t decline with age. In some participants they increase. Associations between taurine and health outcomes were inconsistent across cohorts, species, and age groups.
Does the 2025 study mean the 2023 paper was wrong?
Not entirely. The 2023 animal findings are likely valid — taurine declines in mice and monkeys and supplementation extended their lifespan. The challenge is the human extrapolation. The 2025 data suggests the same mechanism doesn’t operate consistently in people.
What longevity supplements have better human evidence?
Spermidine has longitudinal human decline data and population-level cardiovascular mortality associations. Quercetin and fisetin have emerging human senolytic trial data. Berberine has strong human metabolic evidence. Omega-3 has decades of RCT support.
Is taurine safe?
Yes. Taurine is one of the most abundant amino acids in the body. Supplemental doses of 1–6 grams per day have a well-established safety record. No significant adverse effects documented at typical doses.
References
- Yadav V et al. Taurine deficiency as a driver of aging. Science. 2023;380(6649):eabn9257. PMID: 37289866. pubmed.ncbi.nlm.nih.gov/37289866
- Is taurine an aging biomarker? Science. 2025. PMID: 40472098. DOI: 10.1126/science.adl2116. pubmed.ncbi.nlm.nih.gov/40472098
- NIH news release: Taurine unlikely to be a good aging biomarker. June 2025. nih.gov
